Cargando…

Histone Deacetylase Inhibitors: A Promising Therapeutic Alternative for Endometrial Carcinoma

Endometrial carcinoma is the most common malignant tumor of the female genital tract in the United States. Epigenetic alterations are implicated in endometrial cancer development and progression. Histone deacetylase inhibitors are a novel class of anticancer drugs that increase the level of histone...

Descripción completa

Detalles Bibliográficos
Autores principales:	Psilopatis, Iason, Pergaris, Alexandros, Giaginis, Constantinos, Theocharis, Stamatios
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8604582/ https://www.ncbi.nlm.nih.gov/pubmed/34804263 http://dx.doi.org/10.1155/2021/7850688

Ejemplares similares

Thymic Epithelial Neoplasms: Focusing on the Epigenetic Alterations
por: Psilopatis, Iason, et al.
Publicado: (2022)

The Role of Bitter Melon in Breast and Gynecological Cancer Prevention and Therapy
por: Psilopatis, Iason, et al.
Publicado: (2023)

The EPH/Ephrin System in Gynecological Cancers: Focusing on the Roots of Carcinogenesis for Better Patient Management
por: Psilopatis, Iason, et al.
Publicado: (2022)

The Role of Peroxisome Proliferator-Activated Receptors in Endometrial Cancer
por: Psilopatis, Iason, et al.
Publicado: (2023)

The Impact of Histone Modifications in Endometriosis Highlights New Therapeutic Opportunities
por: Psilopatis, Iason, et al.
Publicado: (2023)

Histone Deacetylase (HDAC) Inhibitors: A Promising Weapon to Tackle Therapy Resistance in Melanoma
por: Palamaris, Kostas, et al.
Publicado: (2022)

EPH/Ephrin-Targeting Treatment in Breast Cancer: A New Chapter in Breast Cancer Therapy
por: Psilopatis, Iason, et al.
Publicado: (2022)

Patient-Derived Organoids: The Beginning of a New Era in Ovarian Cancer Disease Modeling and Drug Sensitivity Testing
por: Psilopatis, Iason, et al.
Publicado: (2022)

The Role of Patient-Derived Organoids in Triple-Negative Breast Cancer Drug Screening
por: Psilopatis, Iason, et al.
Publicado: (2023)

The Role of MicroRNAs in Uterine Leiomyosarcoma Diagnosis and Treatment
por: Psilopatis, Iason, et al.
Publicado: (2023)

Histone Deacetylases (HDACs): Promising Biomarkers and Potential Therapeutic Targets in Thymic Epithelial Tumors
por: Palamaris, Kostas, et al.
Publicado: (2023)

The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy
por: Psilopatis, Iason, et al.
Publicado: (2023)

The Role of Peroxisome Proliferator-Activated Receptors in Preeclampsia
por: Psilopatis, Iason, et al.
Publicado: (2023)

Utilizing Exosomal-EPHs/Ephrins as Biomarkers and as a Potential Platform for Targeted Delivery of Therapeutic Exosomes
por: Goutas, Dimitrios, et al.
Publicado: (2022)

The Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome
por: Psilopatis, Iason, et al.
Publicado: (2023)

Histone Deacetylase (HDAC)-1, -2, -4, and -6 in Uveal Melanomas: Associations with Clinicopathological Parameters and Patients’ Survival
por: Levidou, Georgia, et al.
Publicado: (2021)

Unraveling the Epigenetic Role and Clinical Impact of Histone Deacetylases in Neoplasia
por: Goutas, Dimitrios, et al.
Publicado: (2021)

Histone deacetylase (HDAC)-1, −2, −4 and −6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients’ survival
por: Giaginis, Constantinos, et al.
Publicado: (2015)

Role of Histone Deacetylases in the Pathogenesis of Salivary Gland Tumors and Therapeutic Targeting Options
por: Manou, Maria, et al.
Publicado: (2023)

Challenging, Accurate and Feasible: CAF-1 as a Tumour Proliferation Marker of Diagnostic and Prognostic Value
por: Sykaras, Alexandros G., et al.
Publicado: (2021)

Organoids: A New Chapter in Sarcoma Diagnosis and Treatment
por: Psilopatis, Iason, et al.
Publicado: (2022)

High Pregnane X Receptor (PXR) Expression Is Correlated with Poor Prognosis in Invasive Breast Carcinoma
por: Theocharis, Stamatios, et al.
Publicado: (2021)

Extracellular Vesicles as Biomarkers Carriers in Bladder Cancer: Diagnosis, Surveillance, and Treatment
por: Georgantzoglou, Natalia, et al.
Publicado: (2021)

Clinical Significance of the Histone Deacetylase 2 (HDAC-2) Expression in Human Breast Cancer
por: Garmpis, Nikolaos, et al.
Publicado: (2022)

The EPH/Ephrin System in Colorectal Cancer
por: Papadakos, Stavros P., et al.
Publicado: (2022)

Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial Cancer
por: Takai, Noriyuki, et al.
Publicado: (2010)

The Role of PROX1 in Neoplasia: A Key Player Often Overlooked
por: Ntikoudi, Evangelia, et al.
Publicado: (2022)

May EPH/Ephrin Targeting Revolutionize Lung Cancer Treatment?
por: Psilopatis, Iason, et al.
Publicado: (2022)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Exosomes in the Treatment of Pancreatic Cancer: A Moonshot to PDAC Treatment?
por: Papadakos, Stavros P., et al.
Publicado: (2022)

Novel Proteasome Inhibitors and Histone Deacetylase Inhibitors: Progress in Myeloma Therapeutics
por: Chhabra, Saurabh
Publicado: (2017)

The Clinical Impact of the EPH/Ephrin System in Cancer: Unwinding the Thread
por: Pergaris, Alexandros, et al.
Publicado: (2021)

EPHA2, EPHA4, and EPHA7 Expression in Triple-Negative Breast Cancer
por: Nikas, Ilias, et al.
Publicado: (2022)

HuR Protein in Hepatocellular Carcinoma: Implications in Development, Prognosis and Treatment
por: Papatheofani, Vasiliki, et al.
Publicado: (2021)

Histone deacetylase inhibitors as novel anticancer therapeutics
por: Walkinshaw, D.R., et al.
Publicado: (2008)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Therapeutic Strategies to Enhance the Anticancer Efficacy of Histone Deacetylase Inhibitors
por: Miller, Claudia P., et al.
Publicado: (2011)

Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities
por: Garmpis, Nikolaos, et al.
Publicado: (2021)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Histone deacetylase inhibitors: a promising partner for MEK inhibitors in uveal melanoma?
por: Faião-Flores, Fernanda, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rse1oer5vfc56nc19hc3rm1j3v